Molecular Formula | C8H10ClN3O
|
Molar Mass | 199.64 |
Density | 1.286±0.06 g/cm3(Predicted) |
Boling Point | 397.4±37.0 °C(Predicted) |
Solubility | DMSO: ≥22mg/mL |
Appearance | powder |
Color | white to tan |
pKa | 12.90±0.46(Predicted) |
Storage Condition | room temp |
Physical and Chemical Properties | Lazabemide monohydrochloride (Lazabemide Monohydrochloride):C8Hl0ClN3O?HCl. [103878-83-7]. Crystallized from methanol-ether, melting point 193~195 ℃. Distribution coefficient (n-octanol vein): about 0.1. PKa 8.9. Acute toxic LD50 mice (mg/kg):1000~2000 oral administration. |
In vitro study | The in vitro binding characteristics of both radiolabeled inhibitors revealed them to be selective, high-affinity ligands for the respective enzymes. K D and B max values for 3 H-Ro 19-6327 in rat cerebral cortex are 18.4 nM and 3.45 pmol/mg protein, respectively. The IC 50 values for lazabemide are: 86 μM for NA uptake; 123 μM for 5HT uptake; > 500 μM for DA uptake, respectively.. Lazabemide (5 μM) inhibits human MAO-B and MAO-A with IC 50 of 6.9 nM and >10 nM, respectively. And it inhibits rat MAO-B and MAO-A with IC 50 of 37 nM and >10 μM, respectively ina enzymatic assay.Lazabemide differs from L-deprenyl in their ability to induce release of endogenous monoamines from synaptosomes. Thus, Lazabemide (500 μM) induces a greater 5 HT release than does L-deprenyl, but is less effective than L-deprenyl in releasing DA. On the contrary, lazabemide was almost completely inactive on either 5-HT and DA release. Lazabemide (250 nM) results in a clear inhibition of DOPAC formation, while does not increase the accumulation of newly-formed DA in those tubular epithelial cells loaded with 50 microM L-DOPA. |
In vivo study | Lazabemide (3 mg/kg) attenuates ichemia reperfusion-induced hydroxyl radical generation and pretreatment with Lazabemide showed decreased DOPAC levels in comparison with those of their respective vehicle-treated control groups. |